Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients

Najah R.H., and Mohammad A.A.H., and Ammar R.M.R., (2008) Effect of atorvastatin on oxidative stress parameters and lipid profile in type 2 diabetic patients. International Medical Journal, 7 (2). pp. 43-49. ISSN 1823-4631

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
672Kb

Official URL: http://www.e-imj.com/

Affiliations

Kufa Faculty of Medicine, Iraq. Dept. of Pharmacology
Kufa Faculty of Medicine, Iraq. Dept. of Pharmacology
Kufa Faculty of Medicine, Iraq. Dept. of Pharmacology

Abstract

Introduction: Evidence has long existed regarding the relationship between oxidative stress and diabetes. The present study was conducted to assess the effect of atorvastatin on selected oxidative stress parameters in the form of reduced glutathione (GSH), lipid peroxidation byproduct malondialdehyde (MDA) levels, glutathione –S- transferase (GST) activity and catalase (CAT) activity) and its effect on lipid profile (total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) in dyslipidaemic type 2 diabetic patients . Materials and Methods: Fifty nine dyslipidaemic type 2 diabetic patients were included in this study. Full history was taken and general examination of patients was performed. Patients studied were taking glibenclamide (an oral hypoglycaemic drug) during the study as a treatment for their disease. These patients were followed up for 60 days and divided randomly into 2 groups. Group I (n = 31): no drug was given and served as dyslipidaemic diabetic control. Group II (n = 28): received atorvastatin tablets 20 mg once daily at night. Of the 59 Fifty patients, 46 completed the study while 13 patients withdrew. This is due to non compliance of the patients. Blood samples were drawn from the patients at the beginning and after 60 days of follow up between 8:30 & 10:30 am after at least 12-14 hours fast. Fasting blood glucose, lipid profile, selected oxidative stress parameters (GSH, MDA levels, GST and CAT activities) were measured. Renal and hepatic functions were also assessed. Results: This study revealed that: atorvastatin treatment increased serum GSH; reduced MDA levels significantly while did not significantly affect CAT and GST activity. In atorvastatin treatment, TC, TG, LDL and VLDL decreased significantly while HDL increased significantly. Conclusion: There was insignificant correlations between atorvastatin induced changes in the oxidation markers and the observed changes of the lipid profile.

Item Type:Journal
Keywords:Atorvastatin, Type 2 Diabetes, Oxidative Stress
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:11194

1. Betteridge DJ. What is oxidative stress? Metabolism 2000; 49:3-8

2. Halliwell B. Free radicals, antioxidants and human disease: Curiosity, cause or consequence. Lancet 1994; 344:721-4

3. Mercure F, Quagliaro L, Ceriello A. Oxidative stress evaluation in Diabetes. Diabetes Technol Ther 2000; 2:4

4. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep 1999; 1:146-6

5. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology 2000; 7:153-63

6. Shah S, Iqbal M, Karam J, Salifu M, Mcfarlane SI. Oxidative stress, glucose metabolism and the prevention of type 2 diabetes: pathophyi ological insights. Antioxid Redox Signal 2007; 9:911-29

7. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 2001; 54:176-86

8. Florence JA, Yeager BF. Treatment of type 2 diabetes mellitus. Am Fam Physician 1999; 59:10

9. Mehta JL, Rasouli N, Sinha AK, Molavi B. Oxidative stress in diabetes: A mechanistic overview of its effects on atherogenesis and myocardial dysfunction. Int J Biochem Cell Biol 2006; 38:794–803

10. Oberley LW. Free radicals and diabetes. Free Rad Bio Med 1988; 5:113–24

11. Eisei N, Hirokazu T. Parameters for measure ment of oxidative stress in diabetes mellitus: applicability of ELISA for clinical evaluation. J Investig Med 2005; 53:167-75

12. Johansen LS, Harris AK, Rychly D, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005; 4:5

13. Patel J. Dyslipidaemia in diabetes. Clin Evid 2006; 15:555-75

14. Florkowski CM. Management of co-existing diabetes mellitus & dyslipidaemia : defining the role of thiazolidinediones . Am J Cardio vasc Drugs 2002; 2:15-21

15. Violi F, Loffredo L, Musella L, Marcoccia A. Should antioxidant status be considered in interventional trials with antioxidants? Heart 2004; 90:598-602

16. Sheffield MC. Multiple effects of statins in non lipid disease states. US Pharm 2004; 6:38-54

17. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110:285-8

18. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic mi croangiopathy. FASEB J 2004; 18:805-15

19. Beltowski J. Statins and modulation of oxidative stress. Toxicol Mech Methods 2005; 15:61-92

20. Hodgson BB, Kizior RJ. Saunders nursing drug handbook. Philadelphia: Lippincott, 2003.

21. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Indian J Med Sci 2001; 169:176-9

22. Ellsworth AJ, Witt DM, Dugdale DC, Oliver LM. Mosby’s Medical Drug Reference. St Louis: Mosby, 2006

23. Munford RS. Statins and the acute phase re sponse. N Engl J Med 2001; 344:2016-18

24. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promotes potent systemic anti oxidant effects through specific inflammatory pathways. Circulation 2003; 108:426-31

25. Vishal T, Bano G, Khajuria V, Parihar A, GuptaS . Pleiotropic effects of statins. Indian J Pharmacol 2005; 37:77-85

26. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, et al. Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 2005; 20:133-36

27. Aguilar-Salinas CA, Gomez-Perez FJ, Posadas-Romero C, et al. Efficacy and safety of atorvastatin in hyperlipidaemic type 2 diabetic patients. A 34-week multicenter open label study. Atherosclerosis 2000; 152:489-96

28. Marketou ME, Zacharis EA, Nikitovic D, et al. Early effects of simvastatin versus atorvastatin on oxidative stress and proinflammatory cytokines in hyperlipidaemic subjects. Angiology 2006; 57:211-18

29. Uzunova VV, Tolekova AN, IIieva GS, Trifonova AP. Renin-angiotensin system and lipid peroxidation . Bulgaria J Vet Med 2005; 1:69-75

30. Kasiske BI, Ma JZ, Roberto SN, and Thomas AL. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995;122:133-41

31. Kebapci N, Efe B, Akyuz F, Sunal E, Demirustu C. Oxidative stress and antioxidant therapy in type 2 diabetes mellitus. Turkish J Endocr Metabol 1999; 4:153-62

32. Ellman GL. Arch Biochem Biophys 1959; 82:70-7

33. Guidet B, Shah SV. Am J Physiol 1989; 257:440

34. Habig WH, Pabst MJ, Jakoby WB. Glutathione-S-transferase. The first enzymatic step in mercapturic acid

formation. J Biol Chem 1974; 22:7130-9

35. Aebi H. Catalase. In: Bergmeyer HV ed. Methods in Enzymatic Analysis. New York: Academic Press 1974

36. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-C in plasma without use the preparative ultracentrifuge. Clin Chem 1972; 18:499-502

37. Save V, Patil N, Moulik N, Rajadhyaksha G. Effect of atorvastatin on type 2 diabetic dyslipidaemia. J Cardiovasc Pharmacol Ther 2006; 11:262-70

38. Koter M, Broncel M, Chjnowska-Jezierska J, Klikczynska K, Franiak I. The effect of atorvastatin on erythrocyte membranes & serum lipids in patients with type 2 hypercholesterolaemia. Eur J Clin Pharmacol 2002; 58:501-6

39. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005; 45:89-118

40. Mason JC. Statins and their role in vascular protection. Clin Scien 2003; 105:251-66

41. Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP. Statins lower plasma and lymphocyte ubiquinol / ubiquinone without affecting other antioxidants and PUFA. Bio factors 2003; 18:113-24

42. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-5

43. DALI Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidaemia; the DALI study : a double blind randomized placebo controlled trial in patients with type 2 diabetes and diabetic dyslipidaemia. Diabetes Care 2001; 24:1335-41

44. Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006; 28:627

45. Sakabe K, Fukuda N, Wakayama K,Nada T, Shinohara H . Effects of atorvastatin therapy on the low - density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients. Circulation 2003; 67:866-70

46. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003; 5:372-8

Repository Staff Only: item control page
 
 
 
 
 
 
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.